




5th H3D SYMPOSIUM

Radisson Blu Mosi-Oa-Tunya
LIVINGSTONE RESORT, ZAMBIA

Emerging Treatments for Drug Resistant
Infections of Bacterial and Mycobacterial Origin



SECOND DELEGATE ANNOUNCEMENT

Message from the Symposium Chair

Dear Participants, Colleagues, and Guests,

On behalf of the H3D Foundation, I am pleased to extend a warm and enthusiastic welcome to the 5th H3D Symposium.

As we come together for this important event, we are brought together by a shared commitment to advancing our understanding of infectious diseases, their impact on public health, and the innovations that drive progress in this critical field of medicine.

Our congress theme, "Emerging Treatments for Drug Resistant Infections of Bacterial and Mycobacterial Origin" encapsulates the diverse and dynamic nature of infectious disease research. Over four days, we will delve into a broad spectrum of topics, from emerging infectious threats and epidemiology to addressing the pressing challenge of antimicrobial resistance (AMR). This congress will serve as a platform for exchanging knowledge, fostering collaborations, and discussing breakthroughs that will shape the future of infectious disease control.

We are honoured to host a distinguished line-up of experts and renowned researchers, who will deliver keynote lectures, present their latest findings, and engage in thought-provoking discussions. Their insights and experiences will undoubtedly enrich our understanding and inspire us to tackle the challenges of drug-resistant infectious diseases with renewed vigour.

In addition to the scientific program, we have also planned various networking opportunities, poster sessions, and interactive workshops to encourage dialogue, exchange ideas, and facilitate networking among attendees. We believe these interactions will be instrumental in forging connections and partnerships that will lead to innovative solutions.

Our venue, Livingstone, has been carefully chosen to provide a conducive and welcoming environment for productive discussions and collaborative endeavours. Situated on the banks of the Zambezi River, it offers a captivating backdrop, cultural attractions, and local cuisine, ensuring that your stay will be both enjoyable and enriching. As we embark on this exciting journey of discovery and collaboration, I encourage you to actively participate, engage in lively discussions, and make the most of this unique opportunity to learn, connect, and contribute to the field of infectious disease research.

Once again, a warm welcome to the 5th H3D Symposium, 2024. We look forward to your active involvement and hope your experience will be rewarding, inspiring, and memorable.

Should you have any questions or require assistance during your stay, please do not hesitate to contact our dedicated symposium support team.

Sincerely,

KELLY CHIBALE
SYMPOSIUM CHAIR

About H3D & H3D Foundation



Established in 2010, the Holistic Drug Discovery and Development Centre (H3D) at the University of Cape Town (UCT) has been at the forefront of infectious disease drug discovery in Africa.

In recognition of its significant contributions, H3D became a Johnson and Johnson (J&J) Centre for Global Health Discovery in 2022, joining an elite group of only three such centres worldwide. With a mission to improve treatment outcomes in African patients, develop drug discovery technologies, and train African scientists, H3D has made great strides in the field.

In 2019, H3D Foundation NPC was incorporated as the vehicle for driving the drug discovery capacity building projects and continuing the work initiated by the H3D centre. The vision of the H3D Foundation is to enable and unlock the potential for sustainable drug discovery and development across Africa.

Why Attend the 5th H3D SYMPOSIUM?

The symposium is a pinnacle event for H3D, following the success of the previous four symposia held in Cape Town and Livingstone. The 5th H3D Symposium will be held at the prestigious Radisson Blu Mosi-Oa-Tunya Livingstone Resort in Zambia, providing a captivating backdrop near the magnificent Victoria Falls on the banks of the Zambezi River. This symposium will focus on the theme “Emerging Treatments for Drug-Resistant Infections of Bacterial and Mycobacterial Origin,” addressing the pressing challenge of antimicrobial resistance (AMR).

Face-to-face exposure to more than 150 local, regional, and international delegates from tertiary institutions and the pharmaceutical industry, scientists, and researchers with a specific interest in TB, AMR & NTDS.

Utilise 5th H3D SYMPOSIUM as a platform to present your latest research, product development, science, and capabilities to a global audience.

Provides your company and your products visibility by supporting the 5th H3D SYMPOSIUM, the premier international meeting dedicated to the latest practices for addressing the pressing challenge of antimicrobial resistance (AMR).

An innovative programme comprising instructional course lectures (ICLs), the latest research, keynote lectures, oral and rapid-fire sessions and ePosters.

The symposium aims to foster interaction between high-profile, distinguished international scientists and diverse participants, including postgraduate students and postdoctoral fellows.




Venue

The 5th H3D Symposium will be held at the prestigious **Radisson Blu Mosi-Oa-Tunya Livingstone Resort in Zambia**, providing a captivating backdrop near the magnificent Victoria Falls on the banks of the Zambezi.

Radisson Blu Mosi-Oa-Tunya offers a spacious setting with modern audiovisual equipment and seating for up to 250 people.



Venue Location - Livingstone



Situated along the southern border of Zambia, Victoria Falls is a spectacular sight of awe-inspiring beauty and grandeur on the Zambezi River.

It forms the border between Zambia and Zimbabwe and stretches almost two kilometres into a gorge over one hundred metres below - making it one of the world's widest waterfalls. Dubbed 'The Smoke that Thunders' by locals, this UNESCO World Heritage Site is a popular tourist destination for those visiting Zambia. It is world-renowned for its sheer beauty and offers visitors the opportunity to immerse themselves in spectacular landscapes inhabited by abundant wildlife. Visitors can look forward to a wide range of adventure sports such as kayaking, white water rafting, ziplining, bungee jumping and bridge swinging, and those looking for more relaxation can enjoy a sunset boat cruise, game viewing, or browsing through the vibrant local Livingstone Market.

SCIENTIFIC PROGRAMME OUTLINE

WEDNESDAY, 22 MAY 2024

9:00 - 10:30	Theme: Tuberculosis drug discovery - consortium approach
9:00 - 9:30	<i>Dr Steve Berthel (Panorama Global, United States)</i> "The Tuberculosis Drug Accelerator, a model for global health collaborative drug discovery"
9:30 - 10:00	<i>Dr Anna Upton (Evotec, France)</i> "Working within Consortia to build Translational Data for New TB Drugs and Combinations"
10:00 - 10:30	<i>Prof. Erick Strauss (Stellenbosch University, South Africa)</i> "An African consortium to address the need for new anti-tuberculosis treatments"
10:30 - 11:00	Refreshment break
11:00 - 12:30	Theme: Tuberculosis drug discovery - tackling the TB drug resistance
11:00 - 11:30	<i>Prof. Anil Koul (Global Public Health Discovery & Partnerships at Johnson & Johnson, Belgium)</i> "Innovation in Global Public Health - Impact of Bedaquiline discovery on drug-resistant tuberculosis."
11:30 - 12:00	<i>Dr. Khisimuzi Mdluli (Gates Medical Research Institute, United States)</i> "TB Drug Regimen Development to Eliminate Persisters, Reduce Treatment Duration and Combat Resistance Development"
12:00 - 12:30	<i>Prof. Bree Aldridge (Tufts University, United States)</i> "Design and Patterns of Optimized Drug Combinations for TB"
12:30 - 13:30	Lunch
13:30 - 15:30	Theme: Tuberculosis drug discovery - lead generation approaches
13:30 - 14:00	<i>Dr. Robert Bates (GSK, Spain)</i> "Highlights and learnings from a decade of phenotypic screens at GSK"
14:00 - 14:30	<i>Prof. Dirk Schnappinger (Weill Cornell Medicine, United States)</i> "Genetic approaches to help develop new medicines that can treat or prevent Tuberculosis."
14:30 - 15:00	<i>Prof. Nicole Sampson (Stony Brook University, United States)</i> "Tuberculosis Target Discovery in Secondary Metabolic Pathways"
15:00 - 15:30	<i>Prof. Mary Jackson (Colorado State University, United States)</i> "New approaches to the development of therapeutics targeting nontuberculous mycobacteria"
15:30 - 17:30	Poster session and refreshments
18:00 - 21:00	Speaker's dinner (by invitation) and evening at leisure for other delegates

THURSDAY, 23 MAY 2024

9:00 - 9:30	Special Talk by Nature editors Francesca Cesari & Joao Monteiro
9:30 - 10:30	Theme: Antimicrobial Resistance Drug Discovery - Global Health Perspective
9:30 - 10:00	<i>Dr. Erin Duffy (CARB-X)</i> "CARB-X: building and sustaining a pipeline of high-impact products to prevent, diagnose and treat bacterial infections."
10:00 - 10:30	<i>Dr Seamus O'Brien (Global Antibiotic Research & Development Partnership)</i> "Antibiotic development and access to address priority drug-resistant infections: An integrated approach."
10:30 - 11:00	Refreshment break

SCIENTIFIC PROGRAMME OUTLINE

THURSDAY, 23 MAY 2024 - CONT

11:00 - 12:00	Theme: Antimicrobial Resistance Drug Discovery - Global Health Perspective continued
11:00 - 11:30	<i>Prof. Ursula Theuretzbacher (Center for Anti-Infective Agents, Austria)</i> "Antibacterial Drug Resistance - assessing the Global Health Perspective of the Clinical Pipeline"
11:30 - 12:00	<i>Dr. Mike Strange (LifeArc, United Kingdom)</i> Addressing translational challenges in AMR
12:00 - 12:30	Student flash talks
12:35 - 13:30	Lunch
13:30 - 16:30	At Leisure to explore all Livingstone has to offer.
16:30 - 18:30	Theme: Antimicrobial Resistance Drug Discovery Approaches
16:30 - 17:00	<i>Dr. Nikki Cardoso (University of Cape Town, South Africa)</i> "The outer membrane of the Gram-negative priority pathogen <i>Acinetobacter baumannii</i> as a rich source of antimicrobial targets"
17:00 - 17:30	<i>Dr. Greg Basarab (University of Cape Town, South Africa)</i> "Investigations in AMR Across the Four Pillars of Drug Discovery: Biology, Medicinal Chemistry, Pharmacology and Toxicology."
17:30 - 18:00	<i>Dr Rolf Müller (Helmholtz Institute of Pharmaceuticals Sciences, Germany)</i> "Novel antibiotics from soil bacteria: Unearthing nature's biosynthetic potential towards clinical application."
18:00 - 18:30	<i>Dr. Neil Osheroff (Vanderbilt University School of Medicine, USA)</i> "Gyrase and Topoisomerase IV: Repurposing Old Targets for New Antibacterials"
18:35 - 19:30	At Leisure to explore all Livingstone has to offer.
19:30 - 21:00	Symposium Dinner

FRIDAY, 24 MAY 2024

8:00 - 10:00	Industry Partner Workshop: AI tools for antimicrobial drug discovery Facilitators: Dr. Miquel Duran-Frigola, Dr. Gemma Turon (Ersilia Open Source Initiative); Jason Hlozek (H3D)
10:00 - 10:30	Student flash talks
10:30 - 11:00	Refreshment break
11:00 - 13:00	Theme: Technology platforms to support TB and AMR drug discovery
11:00 - 11:30	<i>Dr. Mwila Mulubwa (University of Cape Town, South Africa)</i> "Unlocking precision tuberculosis treatment: Leveraging pharmacometrics and AI/ML for the genetically diverse African population."
11:30 - 12:00	<i>Dr. Monicah Otieno (Gates Medical Research Institute, United States)</i> "Nonclinical safety considerations in selection and development of TB drug candidates for combination therapy."
12:00 - 12:30	<i>Dr. Greg Perry (The International Federation of Pharmaceutical Manufacturers & Associations, Geneva, Switzerland)</i> "Keys for powerful locally driven partnerships for health innovation in Africa"
12:30 - 13:00	Poster prizes and closing remarks by Prof. Kelly Chibale (Director, H3D)
13:00 - 14:00	Lunch & staggered departures

TOURS & EXCURSIONS

CLICK ON THE THUMBNAILS BELOW TO FIND OUT MORE

Flight of Angels

\$195p/p

15 minute helicopter flight over The Victoria Falls

Segway Tours

\$42p/p

The Elephant Café incl. dinner

\$260 p/p

Speed boat pick-up transfer, elephant interaction, Al La Carte dinner at Elephant Café, Road transfer back to accommodation. Excludes drinks.

Lunar Rainbow Tour

\$58p/p

(guided tour of the falls, 1,5 hours)

Mosi-Oa-Tunya Game Drive

\$79p/p

3 hour morning game drive including hot beverages

Micro lighting over the falls

\$185p/p 15min trip

\$366p/p 30min trip

Tours of the Falls

\$51p/p

1,5 hour walking tour

Batoka Gorge Activities

(Bridge swing)

\$95p/p Single

\$150p/p Tandem

2-hour horse ride

\$95p/p

Livingstone island

\$207p/p

Angels/ Devils Pool experience

2-hour Quad bike ride

\$160p/p

on Village Trails

Flight of Angels, Helicopter

Trip over the falls

\$195p/p

TOURS & EXCURSIONS

CLICK ON THE THUMBNAILS BELOW TO FIND OUT MORE

Mukuni Village Tour

\$56p/p

(2 hours)

Livingstone Historical Tour

\$56p/p

(2 hours)

Maramba Market Tour

\$56p/p

(2 hours)

Victoria Falls Bridge Tour

\$116p/p

(2 hours)

List of Speakers



Prof Bree Aldridge, Tufts University

Bree Aldridge received her Ph.D. in Biological Engineering from the Massachusetts Institute of Technology, studying with Douglas Lauffenburger and Peter Sorger and with the support of a U.S. Department of Energy Computational Science Graduate Fellowship. She completed postdoctoral training with Sarah Fortune at the Harvard School of Public Health. She is currently a Professor in the Department of Molecular Biology and Microbiology and the Department of Biomedical Engineering at Tufts University. She is also the Associate Director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Associate Director of the Tufts Institute for Artificial

Intelligence, and a Member of the Tuberculosis Drug Accelerator Program of the Bill and Melinda Gates Foundation. She is an Alfred P. Sloan Research Fellow and the recipient of a N.I.H. Director's New Innovator Award.

Professor Aldridge specializes in creating intuitive descriptions of complex cell biology by combining experiments and mathematical modeling. Using microscopy and computational modeling, her lab develops quantitative tools to interrogate and interpret tuberculosis cell growth and division behaviors. Her lab is interested in learning how bacterial growth state and morphological features predict drug response at the single-cell level. In parallel, the Aldridge lab uses engineering approaches to systematically measure drug combination effects in vitro and design optimized multi-drug treatment strategies.



Dr Greg Basarab, University of Cape Town

Greg Basarab works as an independent consultant with a variety of entities engaged in Infectious Disease drug discovery research including CARB-X, H3D, Science for Africa (SFA) foundation, Enable-2 antimicrobial resistance (AMR) drug discovery platform and ArrePath, a start-up biotech working on AMR. He has managed research groups in Medicinal Chemistry, Pharmacology and Microbiology across a variety of infectious diseases. Previously, he sat on the Executive Committee (EXCO) of H3D to co-direct business and scientific activities while managing the scientific staff and activities around Medicinal Chemistry and Computer-Aided Drug Design (CADD); Pharmacology (ADME and in vivo PK);

and Biosciences (AMR, tuberculosis, and malaria parasitology). Greg had also worked at AstraZeneca where he led multidisciplinary discovery project teams directed at the discovery and design of novel mode-of-action antibacterials with three entering human clinical trials. One project produced Zoliflodacin, a novel mode-of-action antibacterial for the treatment of gonorrhea having completed Phase 3 trial and now awaiting FDA approval. A second project involved development of the enabling process to the newly FDA approved Durlobactam, a second generation DABCO-class β -lactamase inhibitor that, in combination with Sulbactam, is targeted for the treatment of *Acinetobacter baumannii* infections. He also worked at Dupont where he led projects within three departments of the DuPont Corporation: Central Research & Development, Biochemicals and Agricultural Products working in the antifungal arena and in automated chemical synthesis. Greg was trained as a synthetic organic chemist having earned a PhD at MIT and a BS at Penn State University, both degrees in Chemistry.



Dr Robert Bates, GSK

Robert Bates received his B.S. in chemistry from MIT and a Ph.D. in organic synthesis with Prof. William Roush at the Scripps Research Institute of Florida. In 2011, he joined GSK's Global Health Medicines R&D unit in Tres Cantos, Spain as a medicinal chemist in the tuberculosis group. From making designing and synthesizing new drug candidates as a chemist he then transitioned into project leadership, and eventually to TB Portfolio Leader.

In this role, he is responsible for overseeing pre-clinical research activities both in discovery and to support the translational development of GSK's significant pipeline of TB assets. Areas of current discovery interest in GSK include exploring the biology of host-pathogen modulation for potential new drug targets, prosecuting challenging biological targets via novel modalities, and developing tools for designing/identifying promising new drug combinations in the future.

Of particular note, Robert has been involved in the discovery and early development processes of four molecules now in active clinical development. He was directly involved in the discoveries of GSK2556286 and sanfetrinem cilexetil for TB. His role as portfolio leader has further encompassed GSK3036656 and alpipectir (boosted ethionamide).

Along with his internal responsibilities, Robert is also the GSK representative for a number of influential TB collaborations and consortia including the TB Drug Accelerator, PanTB, and ERA4TB. Robert's work within GSK and with collaborators has led to over 30 peer reviewed publications and multiple patents.



Dr Steve Berthel, Panoramaglobal

Of particular note, Robert has been involved in the discovery and early development processes of four molecules now in active clinical development. He was directly involved in the discoveries of GSK2556286 and sanfetrinem cilexetil for TB. His role as portfolio leader has further encompassed GSK3036656 and alpipectir (boosted ethionamide).

Along with his internal responsibilities, Robert is also the GSK representative for a number of influential TB collaborations and consortia including the TB Drug Accelerator, PanTB, and ERA4TB. Robert's work within GSK and with collaborators has led to over 30 peer reviewed publications and multiple patents.



Dr Nikki Cardoso, University of Cape Town

Dr Nicole Cardoso is a molecular and micro- biologist with over a decade of experience in mycobacterial research.

She obtained her PhD from the University of the Witwatersrand in South Africa and her postgraduate research focused on the characterization of vulnerable genes and pathways in *Mycobacterium tuberculosis* that could potentially serve as novel drug targets. The areas of research included respiration, nitrogen metabolism and molybdenum cofactor biosynthesis.

Dr Cardoso joined H3D in 2020 and was a part of the TB Biology team until early 2023. During that time, she has been responsible for routine primary and secondary screening assays, been involved in academic projects focused on basic biology and designing and performing experiments for mechanism of action deconvolution for hit compounds. The projects she has worked on have been in various stages of pre-clinical drug discovery from formal hit assessment to late lead optimization. Dr Cardoso recently joined the AMR Biology team as an Investigator and will be leading the platform moving forward, while prioritizing the addition of molecular biology expertise for Gram negative bacteria, with particular focus on the priority pathogen *Acinetobacter baumannii*.



Dr Erin Duffy, CARB-X

Erin Duffy is the Chief of Research & Development at CARB-X. CARB-X is a global biopharmaceutical accelerator for the discovery and early development of products to prevent, diagnose and treat bacterial infections. Most of her professional growth was with Melinta Therapeutics (founded as Rib-X Pharmaceuticals) where ultimately she became EVP, Chief Scientific Officer and R&D site head. Her entry into the pharmaceutical sector began with Pfizer Central Research. Erin's formal training was at Yale University, where she completed a PhD in physical-organic chemistry and an HHMI postdoctoral fellowship in computational structural biology.

The title of my talk will be, "*CARB-X: building and sustaining a pipeline of high-impact products to prevent, diagnose and treat bacterial infections*"



Prof Mary Jackson, Colorado State University

Dr. Mary Jackson currently is a Professor of Bacteriology in the Department of Microbiology, Immunology and Pathology at Colorado State University. She earned a Bioengineering degree and a MSc. Degree from the National School of Agronomy, Rennes, France in 1994, and a Ph.D. degree in Biochemistry, and Cellular and Molecular Biology from the Pasteur Institute, Paris, France, in 1998. After a postdoctoral training at Colorado State University under Prof. Patrick J. Brennan in 1999-2000, she returned to the Pasteur Institute where she worked as a Research Scientist in Prof. Brigitte Gicquel's laboratory for seven years. In 2007, she moved back to Colorado State University as an Assistant Professor where she

has since been leading her own independent research program.

Dr. Jackson's research focuses on the elucidation of critical pathways leading to the biosynthesis and export of (glyco)lipids, fatty acids and polysaccharides in *Mycobacterium tuberculosis* and other mycobacterial pathogens of clinical interest (*M. ulcerans*, *M. leprae* and nontuberculous mycobacteria) with the goal to inform novel therapeutic strategies.

Dr. Jackson has published over 200 peer-reviewed scientific articles and serves on numerous grant review panels for the National Institutes of Health and other Federal, private and non-profit funding agencies globally.



Dr Anil Koul, JnJ

Prof Anil Koul is currently vice-president and head of discovery research at Global Public Health R&D unit of Johnson and Johnson. Anil is also a Professor of Translation Discovery at London School of Hygiene and Tropical Medicine where he has set up a laboratory to focus on TB translational medicine research. He is currently member of Board of Directors at Janssen Pharmaceutica NV, Belgium, a J&J's European subsidiary, where he has fiduciary responsibility.

Anil's key achievement till date has been his role in discovery and development of Bedaquiline - the first drug to be approved in last 45 years for treatment of drug-resistant tuberculosis. Bedaquiline has been conditionally approved in over 64 countries and has reached more than 600,000 TB patients across the world and is on WHO's list of 'essential medicines' both for adult as well as pediatric TB.

In 2020 Anil was awarded American Chemical Society's annual "Heroes of Chemistry" award for discovery and development of Bedaquiline. He was awarded in 2017 the 'Sun Pharma Research Award' and in 2004 "Swiss TB Prize" by society of pneumology (Switzerland) for his contributions. Anil was also a member of the J&J team that was awarded 2016's "Prix Galien French prize" for the discovery of Bedaquiline. Anil has published in leading scientific journals such as Nature and Science amongst others and holds more than 30 international patents.

During 2017-2019 Anil served as Director of Council of Scientific and Industrial Research (CSIR) - Institute of Microbial Technology, a premier biotechnology laboratory of Ministry of Science and Technology, Government of India. Anil has been on Scientific Advisory Board of CSIR. He is currently a core member of UN's Stop TB Partnership Working Group on New Drugs and in 2023 he has been listed among the "Top 20 Innovators for Bioscience innovations" in India by BioVoice News.



Dr Khisimuzi Mdluli, Gates Medical Research Institute

Khisimuzi Mdluli (Khis) is a Microbiologist with pharmaceutical industry experience in antibiotic development, and anti-TB drug regimen development. He has a keen interest in defining the contribution of individual drugs in clinical TB regimens. Khisi was previously at the Global Alliance for TB Drug Development (TB Alliance) for about 15 years where he managed multiple drug development projects, including national and global collaborations with academic scientists, pharmaceutical partners and contract research organizations. In that position and in collaboration with John Hopkins University (JHU), he identified TB drug combinations in animal models that produced TB treatment durations

shorter than the standard of care for advancement into clinical trials. Two such regimens, Bedaquiline + Pretomanid + Linezolid (The NiX and ZeNiX trials, currently in clinical use for XDR-TB) and Bedaquiline + Pretomanid + Moxifloxacin + Pyrazinamide (The SimpliciTB Regimen, recently completed clinical trials for Drug-Sensitive and MDR-TB patients, respectively). The NiX-TB regimen has been approved by both the FDA and the EMA as the first novel 3-Drug TB regimen for treating XDR-TB, the most dangerous and most difficult to treat version of this disease.

At the Gates MRI, one of Khisi's responsibilities is extending his work on novel TB Drug Regimen development to develop even better combinations with better translatability and treatment shortening potential in the clinic. Khisi has extended his TB Drug Regimen design to specifically target drug tolerant persisters and include host directed therapies (HDT) to achieve treatment shortening with pre-clinical studies run at the Trudeau Research Institute.

Khis holds a PhD in Microbiology and Biochemistry from the University of Victoria, Victoria, BC, Canada.



Dr Rolf Müller, Helmholtz Institute of Pharmaceuticals Science Saarland

Rolf Müller is Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) since 2009, and heads the Department of "Microbial Natural Products" (MINS). Since October 2003, he has held a chair as professor of Pharmaceutical Biotechnology at Saarland University.

Rolf is involved in several national and international research networks and collaborations with the aim to identify novel bioactive natural products, to analyze their biosynthesis and structures and to develop their biological and chemical properties towards novel (pre)clinical candidates. He is elected member of both acatech and Leopoldina as well as honorary professor of the Shandong University joint Helmholtz Institute of Biotechnology, which has recently been recognized as Helmholtz International Laboratory for Antiinfectives. In 2021, he was awarded the Gottfried Wilhelm Leibniz-Prize of the German Research Foundation (DFG) and in August 2023, the Charles Thom Award of the Society for Industrial Microbiology and Biotechnology (SIMB).

Rolf studied pharmacy in Bonn, where he also obtained his PhD in 1994. After a two-year research scholarship at the University of Washington in Seattle, he became junior group leader at the Gesellschaft für Biotechnologische Forschung in Braunschweig. In 2000, he completed his habilitation thesis at the Technische Universität Braunschweig on the biosynthesis of antibiotics in actinomycetes and myxobacteria.



Dr Mwila Mulubwa, University of Cape Town

Mwila Mulubwa is an Investigator scientist in the Drug Metabolism and Pharmacokinetics (DMPK) unit of the Drug Discovery and Development Centre (H3D) at the University of Cape Town. Driven by the passion to contribute to the advancement of drug discovery, he applies pharmacometrics methodologies such as pharmacokinetic modelling, simulation and physiologically based pharmacokinetic modelling (PBPK). He leads the pharmacokinetic-pharmacodynamic modelling activities to optimize experimental designs and facilitate data-driven decision-making in the drug discovery and development process.

Mwila obtained his PhD in Pharmaceutical Sciences from the University of the Western Cape, where his work contributed to a better understanding of antituberculosis parent drug/ metabolite disposition and the mechanism of adverse drug reactions in patients with drug-resistant tuberculosis. Additionally, he has made significant contributions to the field of pharmacometrics through peer-reviewed scientific publications. He also holds an MSc in Pharmacology and a BPharm from North-West University and The University of Zambia, respectively.

Mwila's research focuses on antimicrobial therapy optimization of drugs that exhibit large pharmacokinetic variation in genetically diverse African populations. He spearheads the development of advanced PBPK models of antituberculosis and antimalarial drugs that integrate artificial intelligence/machine learning-generated data to determine optimum dose regimens.



Dr Seamus O'Brien, GARDP

Seamus O'Brien joined the Global Antibiotic Research and Development Partnership (GARDP) as R&D Director in July 2018 and is responsible for strategic development to delivery of a portfolio of antibiotic treatments for those priority infections significantly impacted by antibiotic resistance. The R&D portfolio includes full development projects and support for access led projects within our two key disease areas of sepsis/serious bacterial infections and sexually transmitted infections. Also, with a complimentary bespoke focus on discovery and exploratory research activities. A priority focus for Seamus since 2018 has been to lead the R&D team to complete development, as sponsor, of

zolidonacin for drug resistant gonorrhoea and to commence a novel groundbreaking clinical trial on novel regimens for neonatal sepsis. Previously, he was responsible, in AstraZeneca and then Pfizer, for building and leading public-private R&D collaborations to address the need to develop treatment options for drug resistant infections.

He played a leading role in establishing novel partnerships for with the US government's Biomedical Advanced Research and Development Authority (BARDA) and with the Innovative Medicines Initiative (IMI) New Drugs 4 Bad Bugs programme within Europe as leader of both the COMBACTE-CARE consortium and a BARDA portfolio agreement addressing antibiotic development for multi-drug resistant infections. He has also represented both AstraZeneca and then Pfizer on the Infection Control Strategic Governance Group for IMI and the European Federation for Pharmaceutical Industry (EFPIA). He played a leading role in building a standalone Infection unit within AstraZeneca and was responsible for bringing a novel antibiotic combination candidate through phase 1 to phase 2 and designing a full clinical development programme aligned with emerging regulatory guidance.

Seamus has extensive experience in drug development from preclinical to medical affairs including vaccine and antibiotic development and has a Ph.D in Mycobacterium tuberculosis infection and host immunity from the University of Leicester and first degree in Microbiology from Trinity College Dublin.



Prof Neil Osheroff, Vanderbilt University School of Medicine

Neil Osheroff received his PhD in Biochemistry and Molecular Biology from Northwestern University and was a Helen Hay Whitney Foundation Postdoctoral Fellow in the Department of Biochemistry, Stanford University School of Medicine. He currently is Professor of Biochemistry and Medicine at the Vanderbilt University School of Medicine and holds the John G. Coniglio Chair in Biochemistry. Neil's laboratory focuses on the functions, mechanism, and drug interactions of enzymes known as topoisomerases.

These enzymes regulate DNA under/overwinding and remove knots and tangles from the genome. Beyond their critical roles in a variety of DNA processes, the bacterial type II topoisomerases, gyrase and topoisomerase IV, are the targets for fluoroquinolones (including ciprofloxacin and levofloxacin), which are among the most widely used antibacterials worldwide. Unfortunately, the clinical use of fluoroquinolones is being impacted by target-mediated drug-resistance. Consequently, gyrase and topoisomerase IV are the targets for two emerging classes of antibacterials, novel bacterial topoisomerase inhibitors (NBTIs) and spiropyrimidinetriones (SPTs), which interact with different amino acid residues on the type II topoisomerases than fluoroquinolones. Neil's laboratory has made seminal contributions to our understanding of how each of these drug classes interact with gyrase and topoisomerase IV and affect the catalytic activities of these enzymes. His research group has published some of the most detailed mechanistic analyses to date regarding fluoroquinolones, NBTIs, and SPTs. As part of his research program, Neil has a long-standing interest in mentoring and training young scientists, especially pre-doctoral students. Thirty-three students have received their Ph.D. degrees under his mentorship. Neil has received awards for mentoring, teaching, curricular design, educational leadership and service, and affirmative action, and he is a Fellow of the American Association for the Advancement of Science and a Fellow of the Association for Medical Education in Europe. Over the course of his career, Neil has published >280 scientific and educational papers and has presented >400 talks in 40 different countries.



Dr Monicah Otieno, Gates Medical Research Institute

Monicah received her PhD in Pharmacology from the University of Rochester, Rochester NY, followed by a post-doctoral fellowship in Toxicology at Johns Hopkins University in Baltimore, MD. She then joined the pharmaceutical industry as a toxicologist and has held positions of increasing responsibility over the last 20+ years. She is presently the head of nonclinical development at Bill and Melinda Gates Medical Research Institute (Gates MRI), a nonprofit biotech, where she oversees nonclinical safety and DMPK groups. Driven by her keen interest in innovation and problem solving in toxicology, Monicah developed scientific collaborations with investigators in academia and biotech where she sponsored

original research and innovation to address gaps in the field of drug-induced liver injury. She has authored and co-authored over 40 scientific articles and book chapters and is a co-inventor on two patents on the Organ-on-Chip technology as the future for in vitro testing. Monicah is also active in scientific and industry organizations in the field of toxicology where she continues to serve in various leadership capacities.



Dr Greg Perry, IFPMA

Greg Perry is currently Assistant Director General at the IFPMA and has special responsibility for the organization's Africa Engagement and Alliance Building strategies, focusing on innovation, access, and the regulatory environment.

Directly before he joined IFPMA, Greg was for 5 years Executive Director of the Geneva based Medicines Patent Pool - a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries.

Previously Greg was the founder and long term Director General of the Brussels based European Generic Medicines Association (Renamed Medicines For Europe). During this period Greg was awarded the Golden Cross of Merit of the Republic of Poland for his contribution to industry and European integration.

Greg is currently a representative for industry on the Stakeholders Group of European & Developing Countries Clinical Trials Partnership (EDCTP) . Greg is also Vice-Chair of the Advisory Council of TOPRA (The Organisation for Professionals in Regulatory Affairs) and a former Vice-Chair of the Fight the Fake Alliance - committed to eradicating substandard and falsified products .

Greg is specifically committed to working on bridging public and private strengths for societal goals and is active in developing international partnerships especially between Europe and Africa.

Greg has an MA in European Integration and Cooperation, a BSoc.Sc in International Studies and a Diploma in Classical Studies .



Dr Nicole Sampson, Stony Brook University

Prof Sampson's laboratory studies how proteins function in human biology, and how small molecules can alter their function to improve the human condition. Her laboratory has focused on mapping the mycobacterial cholesterol metabolism pathway, the use of chemical probes to unravel the intricacies of sperm-egg binding in mammalian fertilization, and the development of chemistry to provide perfectly alternating polymer sequences. In the TB field, her laboratory's enzymology studies have evolved to undertake the elucidation of the mechanisms by which mycobacteria, e.g., *M. tuberculosis*, use cholesterol metabolism to persist in their human host. Her laboratory has and continues to pursue a multi-pronged approach that includes elucidating enzyme function and structure, establishing metabolite structures that accumulate in knockout strains to identify the substrates of key enzymes, identifying small molecules that interfere with the host immune response, and developing metabolomic methods to screen these pathways for inhibitors. Current work is focused identifying inhibitors of Mtb to use in therapeutics and elucidating their molecular mechanisms of action.

Prof Sampson's honors and awards include the Camille and Henry Dreyfus New Faculty Award, a National Science Foundation CAREER Award, the Arthur C. Cope Scholar Award and the Pfizer Award in Enzyme Chemistry, both from the American Chemical Society, the Research Foundation of SUNY Research and Scholarship Award, and the New York State NYSTAR Faculty Development Award. In 2017, she was selected as a Fellow of the Stellenbosch Institute for Advanced Study (STIAS) and a Fellow of the American Chemical Society. She has authored over 120 peer-reviewed articles, reviews, and issued patents. Nicole joined the Chemistry Department faculty at Stony Brook University in 1993 where she served as Chair of the Chemistry Department from 2012 to 2017. She was promoted to SUNY Distinguished Professor of Chemistry in 2018 and served as dean of the College of Arts and Sciences at Stony Brook from 2018-2023. She currently serves as Robert L and Mary L Sproull Dean of the School of Arts and Sciences at University of Rochester where she is University Professor of Chemistry.



Prof Dirk Schnappinger, WCM

Dirk Schnappinger joined Weill Cornell Medical College in 2001, where he currently holds the position of Professor in the Department of Microbiology & Immunology. He received his Ph.D. from the Friedrich-Alexander University of Erlangen-Nürnberg, Germany, in 1998 for work on the repressor controlling tetracycline resistance in Gram negative bacteria. After his graduate work Dr. Schnappinger began to study the human pathogen *Mycobacterium tuberculosis* (Mtb), first at UC Berkeley, in the lab of Dr. Lee Riley, and then at Stanford under the guidance of Dr. Gary Schoolnik, where he helped to adapt microarray-based RNA profiling to the analysis of bacterial pathogens.

His current research (<https://www.ehrtschnappingerlabs.org/>) aims to help develop new medicines for the treatment and prevention of Tuberculosis (TB), an infectious disease that still claims over a million lives each year. This work began with developing a regulatory system that allows to turn Mtb genes on and off, both in vitro and during infections. His lab now applies this and other genetic approaches to (i) evaluate Mtb gene products as new targets for TB drug development by documenting the impact of their genetic inactivation on growth and persistence of Mtb in vitro and in mice; (ii) help elucidate the mechanisms by which small-molecules inhibit the growth of Mtb; (iii) construct mutants for target-directed whole-cells screens; and (iv) measure vulnerability of Mtb to the partial, CRISPRi-mediated inactivation of individual genes.

Dr. Schnappinger received awards from the German "Studienstiftung des deutschen Volkes", Fond of the German Chemical Industry, the German Research Foundations (DFG), and the Ellison Medical Foundation.



Dr Mike Strange, LifeArc

Dr Mike Strange is Head of Global Health at LifeArc. Mike oversees our three Global Health Translational Challenges in: Antimicrobial Resistance, Neglected Tropical Diseases and Emerging Viral Threats.

These challenges aim to reduce the burden of infectious diseases by enabling the translation of scientific innovations, accelerating their path to deployment in underserved populations.

Mike previously spent more than 20 years at GlaxoSmithKline (GSK), where he held several senior strategic and operational roles in pharmaceutical and vaccine R&D. For the last 12 years at GSK, he worked in Global Health, where he led the creation of several industry-leading collaborative initiatives including the Tres Cantos Open Lab, the Africa Non-Communicable Diseases Open Lab, and a collaboration with Novartis exploring genetic diversity and response to medicines in African patients.

Mike's most recent role at GSK was Vice President Global Health Catalyst, where he was responsible for partnerships/external funding, business strategy and operations, and product strategy/market access within GSK's Global Health Pharma Unit.

Mike has a PhD in Applied Mathematics, an MSc in Mathematics and Biology, a BSc in Mathematics, as well as an Executive MBA from London Business School.



Prof Erick Strauss, Stellenbosch University

Prof. Erick Strauss is regarded as a leading authority on the biosynthesis and enzymology of the essential metabolic cofactor coenzyme A (CoA), the elucidation of organism-specific differences in how CoA is made and used, and applying this knowledge to the development of novel antimicrobials for the treatment of malaria, tuberculosis and staphylococcal infections. He has an on-going interest in discovering new targets for antimicrobial development, and in finding adjunctive therapies that would assist the human immune system to counter such infections effectively.

Erick is currently professor of Biochemistry at Stellenbosch University in South Africa, having previously held academic positions in the department of Chemistry and Polymer Science, also at Stellenbosch. He obtained his PhD in Chemistry and Chemical Biology from Cornell University in the USA in 2003, and used this as springboard to launch his own independent academic career. He now has nearly 20 years' experience in higher education, research and more recently also management, having served as head of the department of Biochemistry since 2022. More than 50 postgraduate students and postdoctoral fellows have completed their training under his supervision, with some having established their own academic groups or found positions in industry, including in drug development.

His awards and honours include receiving the DuPont Prize for Excellence in Teaching from Cornell University (1999); the Rector's Award for Excellence in Teaching from Stellenbosch University (2007); the President's Award from the South African National Research Foundation (2008); the Beckman-Coulter Silver Medal from the South African Society for Biochemistry and Molecular Biology (2010); and the Raikes Medal from the South African Chemical Institute (2013). He was elected as a founding member of the South African Young Academy of Science in 2012.

Erick has established several strong and ongoing international collaborations, and his current and recent research projects are funded by the Bill & Melinda Gates Foundation, the US National Institutes of Health, and the STFC/RCUK agencies in the UK. He is currently editorial advisory board member of the journals ACS Infectious Diseases and Biochemistry. He also has a growing footprint outside of academia, having served as chair of the council (governing board) of non-profit organisation, and most recently as co-founder and CTO of a start-up focusing on animal probiotics.



Prof Ursula Theuretzbacher, Center for Anti-Infective Agents

Ursula Theuretzbacher is an independent expert in antibacterial drug research, discovery/development strategies aligned with public and global health needs. Her extensive expertise includes evaluation and comparative assessment of antibacterial drugs, optimization of antibacterial therapy concepts, and public and philanthropic funding strategies for antibacterial drug R&D and initiatives to recover the global pipeline. She was member of the coordinating group of the WHO project Priority Pathogen List for R&D and leading scientist for the Clinical and Preclinical Pipeline analysis, and development of Target

Product Profiles at WHO. Previously, she collaborated in several large EU-funded projects focused on antibacterial drug R&D, reviving of old antibiotics, and economic strategies to revitalize the global antibacterial drug pipelines. Additionally, she analysed the global antibacterial drug discovery landscape and scientific hurdles for finding new antibiotics. Ursula Theuretzbacher served as President of the International Society for Anti-Infective Pharmacology (ISAP), as Executive Committee member of the International Society for Infectious Diseases (ISID) and was founding chairperson of the ESCMID PK/PD of Anti-Infectives Study Group (EPASG). She holds a PhD in Microbiology from the University of Vienna and the University of Innsbruck in Austria and lectured at the University of Vienna for a decade.



Dr Anna Upton, Evotec

Anna Upton is SVP, Infectious Diseases at Evotec, responsible for strategic oversight of Evotec's global multimodality Infectious Diseases activities and platforms. Prior to this, Anna was Head of TB Research at Evotec and, as part of her current role, continues to lead the company's TB drug discovery and nonclinical regimen development efforts, conducted with partners and within multi-party consortia.

Anna is a molecular biologist and biochemist by training, with experience in drug discovery, translational science, and development gained, prior to Evotec, through roles at TB Alliance. Her most recent role at TB Alliance was Senior Director, Biology. In this and earlier roles at TB Alliance, Anna contributed to or

led a variety of drug discovery and development programs which led to six successful IND filings. She was responsible for the preclinical microbiology component of the successful NDA for pretomanid.

A native of the United Kingdom, but based in New York City, Anna holds a B.A in Molecular and Cellular Biochemistry as well as a D. Phil (Ph.D.) from University of Oxford.

Abstract Submissions

IMPORTANT DATES:

31 January 2024

Abstract Submission Close

30 April 2024

Delegate Registration Close



[CLICK HERE TO SUBMIT
YOUR ABSTRACT](#)

Travel bursaries

These will be grouped by region (LMIC only) and awarded based on funding available for local and international bursaries. Travel bursaries are only open to postgraduate students registered for study in 2024 who have submitted an abstract for the 2024 Symposium and are from a low or middle-income country. **Travel bursaries close on 31 Jan 2024.**

Apply for a travel bursary by sending a copy of your student registration, a personal motivation for the bursary, your supervisor's support letter and a copy of a valid passport to susan.winks@uct.ac.za before 31 Jan 2024

You will be notified if your abstract submission is accepted, but all supporting documentation would need to have been received before that.

Delegate Registration

REGISTRATION RATES & CATEGORIES:

[Click here to register](#)

Pricing and registration for in-person registration. Please note there will be no virtual attendance at the H3D 2024 Symposium

Status		2023 Registration Fees
Student & Postdoctoral Fellows	Early Bird registration fee up to midnight 29 February 2024	USD 550.00 per person
	Standard registration fee	USD 600.00 per person
Academic and Non-Academic	Early Bird registration fee up to midnight 29 February 2024	USD 600.00 per person
	Standard registration fee	USD 750.00 per person
Accompany Person rate	Inclusive of- Sunset River Cruise + Networking function + Farewell Symposium Dinner	USD 210.00 per person

Included:

- Harry Mwanga Nkumbula International Airport in Livingstone, Zambia - Radisson Blu Mosi-Oa-Tunya Livingstone Resort in Zambia, staggered transfers on **Tuesday, 21 May 2024**
- Radisson Blu Mosi-Oa-Tunya Livingstone Resort in Zambia - Harry Mwanga Nkumbula International Airport in Livingstone, Zambia on **Friday, 24 May - staggered departures**
- Admission to all scientific talks
- Access to the trade/exhibition hall
- Catering during coffee breaks and lunches
- **Access to the E-Posters**
- **Sunset River Cruise on the Zambezi River** on Tuesday, 21 May 2024, from 16:00 - 18:30 - limited bar & food
- **Networking function** on-site on Tuesday, 21 May 2024, from 18:30 - 21:00 - limited bar & food
- **Symposium Dinner** on Thursday, 23 May 2024, from 19:30-22:30 - dinner & limited drinks
- *Please indicate your planned attendance at social events during the registration process.*

Exclude:

The delegate rate does not include accommodation and additional activities (tours & excursions) & items of a personal nature e.g. - hotel room extras

Terms & Conditions

- Cancellations received in writing by **16 October 2023** will receive a full refund on registration fees, less a **15% administration fee**.
- Cancellations received in writing between **17 October- 30 November 2023** will receive a 50% refund on registration fees, less a 15% administration fee.
- Cancellations received in writing after 1 December 2023 will result in full fee payment being due.
- We recommend transferring the registration to a new delegate to avoid the cancellation fee.
- In the event of a cancellation, registrations are transferable to delegates not yet registered. Please note that cancellation of hotel accommodation will be charged in line with the hotel's cancellation T&Cs
- Refunds will be processed after the symposium.
- Refunds can only be made via the original payment method.
- Refunds by bank transfers may incur processing fees from your bank, which we have no control over. No refunds are given for no-shows at the H3D 2024 Symposium.

HOTEL CANCELLATION POLICY

Free cancellation until 00:00:00 14 May 2024. For late cancellation or no show a **USD 202.58** penalty will be charged. If paid with Points

or Cash+Points, the corresponding point deduction will be made.

Full terms and conditions will be available for review on the online registration portal during your online registration.

Should you, for any reason, not be able to register or have difficulties registering, please get in touch with the Symposium Organisers Delegate queries: welmie@icesolution.co.za

H3D Committee | H3D Advisory Board | H3D Staff

If you are a Committee member, Advisory Board member or H3D staff you will be emailed a separate registration link by: tracey@icesolution.co.za

Visa Requirements:**Visa information for Zambia****International Flight bookings**

Look no further than Chantal Lopes – your passport to hassle-free international flight bookings to Livingstone!

Chantal Lopes – chantal.lopes@xlboksborg.co.za if assistance is required.

Suggested International flight connections

The below suggested flight time are subject to change without prior notice. Please check with the airlines.

Johannesburg / Livingstone / Johannesburg - 4Z South African Airlin

Flight	From	To	Departs	Arrives	Days
4Z482	Johannesburg - JNB	Livingstone - LVI	11:00	12:45	Daily
4Z483	Livingstone - LVI	Johannesburg - JNB	13:25	15:20	Daily

Johannesburg / Livingstone / Johannesburg - FA - Safair

Flight	From	To	Departs	Arrives	Days
FA752	Johannesburg - JNB	Livingstone - LVI	12:40	14:25	Monday, Friday
FA753	Livingstone - LVI	Johannesburg - JNB	15:25	17:20	Monday, Friday

Johannesburg / Lusaka / Johannesburg - 4Z South African Airlin

Flight	From	To	Departs	Arrives	Days
4Z160	Johannesburg - JNB	Lusaka - LUN	06:15	08:15	Daily except Sundays
4Z162	Johannesburg - JNB	Lusaka - LUN	11:30	13:30	Daily
4Z164	Johannesburg - JNB	Lusaka - LUN	16:35	18:35	Daily except Saturdays
4Z161	Lusaka - LUN	Johannesburg - JNB	08:50	11:50	Daily except Sundays
4Z163	Lusaka - LUN	Johannesburg - JNB	14:15	16:30	Daily
4Z165	Lusaka - LUN	Johannesburg - JNB	19:05	21:20	Daily except Saturdays

Johannesburg / Lusaka / Johannesburg - P0 - Proflight Zambia

Flight	From	To	Departs	Arrives	Days
P0700	Lusaka - LUN	Livingstone - LVI	06:50	08:00	Tuesday, Friday, Sunday
P0704	Lusaka - LUN	Livingstone - LVI	10:30	11:40	Daily
P0708	Lusaka - LUN	Livingstone - LVI	16:35	17:45	Daily
P0701	Livingstone - LVI	Lusaka - LUN	08:40	09:50	Tuesday, Friday, Sunday
P0705	Livingstone - LVI	Lusaka - LUN	12:20	13:30	Daily
P0709	Livingstone - LVI	Lusaka - LUN	18:25	19:35	Daily

Nelspruit / Livingstone / Nelspruit - 4Z - South African Airlin

Flight	From	To	Departs	Arrives	Days
4Z470	Nelspruit - MQP	Livingstone - LVI	11:35	13:30	Monday, Wednesday, Friday, Sunday
4Z471	Livingstone - LVI	Nelspruit - MQP	14:00	15:40	Monday, Wednesday, Friday, Sunday

Cape Town / Livingstone / Cape Town - KQ Kenya Airways

Flight	From	To	Departs	Arrives	Days
KQ783	Cape Town - CPT	Livingstone - LVI	14:30	17:20	Tuesdays / Sundays
KQ782	Livingstone - LVI	Cape Town - CPT	10:30	13:40	Tuesdays / Sundays

Nairobi / Livingstone / Nairobi - KQ Kenya Airways

Flight	From	To	Departs	Arrives	Days
KQ782	Nairobi - NBO	Livingstone - LVI	07:30	09:45	Tuesdays / Sundays
KQ783	Livingstone - LVI	Nairobi - NBO	18:05	22:20	Tuesdays / Sundays

Dubai / Lusaka / Dubai - EK - Emirates # - Next day arrival

Flight	From	To	Departs	Arrives	Days
EK713	Dubai - DXB	Lusaka - LUN	09:25	14:35	Daily
EK714	Lusaka - LUN	Dubai - DXB	21:35	06:30 #	Daily

Doha / Lusaka / Doha - QR - Qatar # - Next day arrival

Flight	From	To	Departs	Arrives	Days
QR1455	Doha - DOH	Lusaka - LUN	02:25	08:35	Wednesday, Friday, Sunday
QR1451	Doha - DOH	Lusaka - LUN	08:15	14:25	Tuesday, Saturday
QR1456	Lusaka - LUN	Doha - DOH	15:25	23:40	Wednesday, Friday, Sunday
QR1452	Lusaka - LUN	Doha - DOH	21:25	05:40 #	Tuesday, Saturday

H3D MOBILE APP

Elevate Your H3D Experience with Our Mobile App!

Unlock the full potential of the H3D event with our cutting-edge mobile app. It's your key to a seamless, personalized, and enriched experience!

- Explore Invited Speakers: Get to know our lineup of speakers and their insights, all at your fingertips!
- Plan Your Leisure Activities: Enjoy your downtime to the fullest - book exciting tours online and receive an exclusive 5% discount!
- Effortless Registration: Skip the queues! Register online through our Mobi App for quick and hassle-free access to H3D.
- Submit Your Abstracts: Share your groundbreaking research effortlessly! Submit your abstracts directly through the H3D Mobi App.
- Personalize Your Schedule: Craft your academic journey! Tailor your agenda with ease to make the most of every session.
- Interactive Engagement: Delegates can actively engage with one another and the event by posting their thoughts, opinions, and questions. It creates a dynamic and interactive environment.
- Ready to elevate your H3D experience? Simply scan the QR code below and download the H3D Mobile App now!


If you have missed installing the App, please follow the steps below to download the Symposium App, where you will find all the needed information regarding the Symposium. There will be Q&A via the App and surveys too.



DOWNLOAD THE SEMINAR APP:

- Download the app 'Cvent Events'
- Once downloaded, use this Event ID to find the event: 5th H3D Symposium.
- Download the event.
- Enter your first name, last name and email address.
- The next step, you will receive a verification code in your email. **Check your junk/spam folder for this email code.** Enter the code to complete the login.

Provisional Exhibition Layout Plan



Social Programme



WELCOME NETWORKING EVENT

Tuesday 21st May 2024.

The Welcome Networking Event will officially open the H3D 5th Symposium in Livingstone, Zambia, late Tuesday afternoon.

The reception **will be held on a River Cruise on the Zambezi >> and outdoors around the hotel pool area**, allowing industry representatives and delegates to mingle and network.



SPEAKER FACULTY DINNER

Wednesday, 22 May 2024

On Wednesday, the H3D Chairperson will host a dinner at The Royal Livingstone Hotel. Unforgettable views and exquisite fine dining set the tone for a perfect evening. Experience one-of-a-kind Zambian Dining as you dine on an elegantly decorated riverside deck or beneath a monkey tree overlooking the Zambezi River. All invited speakers, H3D Board Members, and guests of the H3D chairperson will be invited to attend. **(Invite only)**



SYMPOSIUM DINNER

Thursday, 23 May 2024

Experience traditional African cuisine in Mosi-Oa-Tunya while sitting around a fire pit.

The venue will be in the Acacia Forest next to the Radisson Blu Convention Centre.

Important Dates



12 January 2024	Provisional Scientific Programme online
31 January 2024	Abstract Submission and Travel Bursaries closes.
28 February 2024	Early Bird Registration deadline
30 April 2024	Standard Delegate Registration deadline
30 April 2024	Final Programme available online

Scientific Committee



KELLY CHIBALE
SYMPOSIUM CHAIR

Director of Holistic Drug Discovery
and Development Centre (H3D)



SANDEEP GHORPADE

Holistic Drug Discovery and
Development Centre (H3D)



SUSAN WINKS

Holistic Drug Discovery and
Development Centre (H3D)



GREG BASARAB

Holistic Drug Discovery and
Development Centre (H3D)

Support Committee



AYESHA BANDERKER

Holistic Drug Discovery and
Development Centre (H3D)

Contacts

CONGRESS ORGANISERS - ICE SOLUTION | MORII EVENTS EMAIL: H3D@MORII.CO.ZA



TRACEY WHITTLE
+27 82 444 0770

Trade & Sponsorships, Venue



JOY LARKMAN
+27 84 522 4147

Transfers, Social Events & Tours



WELMIE TURNER
+27 72 741 2603

Delegate Registration

Accommodation

GROUPS RATES HAVE BEEN NEGOTIATED WITH RADISSON BLU LIVINGSTONE



Hotel online booking link >>

CHECK-IN AND CHECK-OUT

Check-in: 15:00 h | Check-out: 12:00 h. You can ask for an early check-in or a late check-out at the hotel.



RATES - H3D SYMPOSIUM 2023

USD 235.00 PER NIGHT

Includes taxes & Fees as well as Breakfast

Max Guests: 2 Adults

Bed type: 1 king or 2 twin

SUPERIOR ROOM WITH TERRACE

In the Superior Room with Terrace, you'll find everything you need for a memorable stay in Livingstone. Start each day with a soothing drink from the coffee and tea facilities and connect to the internet using the free Wi-Fi. Other standard amenities include a TV with mirror casting, bathroom amenities, and air conditioning.

ROOM FEATURES

- Connecting rooms
- Balcony
- Terrace
- Bathroom amenities
- Coffee and tea facilities
- Free bottled water
- Air conditioning
- Rain shower
- TV with mirror casting
- Minibar or fridge
- In-room safe
- Free Wi-Fi



RATES - H3D SYMPOSIUM 2023

USD 285.00 PER NIGHT

Includes taxes & Fees as well as Breakfast

Max Guests: 2 Adults

Bed type: 1 king or 2 twin

PREMIUM ROOM WITH TERRACE - ZAMBEZI RIVER VIEW

Enjoy all of the standard amenities plus views of the Zambezi River when staying in these elegant Premium Rooms. Are you traveling with friends or family? Connecting rooms are also available.

ROOM FEATURES

- Connecting rooms
- Balcony
- Terrace
- Bathroom amenities
- Coffee and tea facilities
- Free bottled water
- Air conditioning
- Rain shower
- TV with mirror casting
- Minibar or fridge
- In-room safe
- Free Wi-Fi

Cancellation & Refunds

HOTEL CANCELLATION POLICY

Free cancellation until 00:00:00 14 May 2024. For late cancellation or no show a **USD 202.58** penalty will be charged. If paid with Points or Cash+Points, the corresponding point deduction will be made.

Useful Information



CLOTHING AND DRESS RECOMMENDATIONS

Zambia has mild winters, and the summer days can be scorching hot. Lightweight casual clothes can be worn all year round, with a jacket or jersey for early winter mornings and evenings.

INTERNET AVAILABILITY

Most hotels offer their guests internet and/or Wi-Fi (free or paid). Internet cafes are springing up in Zambia, but connections can be erratic and slow.

ZAMBIA

This unique, peanut-shaped country, once known as Northern Rhodesia, offers visitors an authentic African experience with adrenalin-pumping adventure sports, various fascinating cultural activities, and abundant indigenous wildlife, which finds refuge in Zambia's vast national parks. Spend your evenings enjoying the spectacular site of the world's largest waterfall, Victoria Falls, while sipping on sundowners after an exhilarating day of whitewater rafting down the rapids of the mighty Zambezi River. If that sounds a little too adventurous for your taste, take a houseboat cruise along the exquisite Lake Kariba while watching wild elephants drink at the riverbank as you try your hand at catching the elusive tiger fish. However, if you spend your time in this unique country, you will leave with a heavy heart and a desire to return soon to this exceptionally beautiful Southern African country.

BANKING AND CURRENCY

CURRENCY

Zambia's currency unit is the Kwacha (ZMW), formally ZMK, which was rebased in 2013. The denominations are K100, K50, K20, K10, K5 and K2. It is subdivided into 100 ngwee. Coins available are K1, 50 ngwee, 10 ngwee and 5 ngwee.

However, some prices are quoted in US\$. It is, therefore, possible to use dollars and pounds as well.

BANKING

In the cities and larger towns, you can change cash and traveller's cheques at Barclays Bank and Standard Chartered Bank branches. Larger branches have ATMs that accept Visa. Foreign exchange offices are easy to find in cities and larger towns.

Most banks operate from 8:15 AM to 3:30 PM on weekdays and from 8:15 AM to 12:00 PM on Saturdays. They remain closed on Sundays and public holidays.

TRAVEL BY ROAD

Zambia has 38,763 kilometres of roads, about 10,000 kms of which are tarred and another 8000 kms are gravel roads—the rest range from reasonable to bad dirt roads.

CLIMATE AND WEATHER

The rains in Zambia come mostly in December, January, February, and March though the further north you are, the earlier the rains arrive and the later they leave. Eastern and higher areas generally receive more rain than western and lowland areas.

By April and May, most of the rain has faded away, leaving a landscape that's still green but starting to dry out. Nighttime temperatures start to drop, especially in higher and more southerly locations.